Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention

JACC: Cardiovascular Interventions

Volumn 9, Issue 14, 2016, Pages 1473-1483

  Koskinas, Konstantinos C ^a   Räber, Lorenz ^a   Zanchin, Thomas ^a   Pilgrim, Thomas ^a   Stortecky, Stefan ^a   Hunziker, Lukas ^a   Blöchlinger, Stefan ^a   Billinger, Michael ^a   Gartwyl, Fabienne ^a   Moro, Christina ^a   Moschovitis, Aris ^a   Jüni, Peter ^b   Heg, Dik ^c   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

anticoagulation; antiplatelet; bleeding; coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; FEMALE; HEART DEATH; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CORONARY THROMBOSIS; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; STROKE; SWITZERLAND; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 85008668738     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.04.027     Document Type: Article

References (32)

1. 1 Lip, G.Y., Windecker, S., Huber, K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35 (2014), 3155–3179.
2. 2 Capodanno, D., Lip, G.Y., Windecker, S., et al. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. Eurointervention 10 (2015), 1015–1021.
3. 3 Cannegieter, S.C., Rosendaal, F.R., Wintzen, A.R., et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333 (1995), 11–17.
4. 4 Connolly, S., Pogue, J., Hart, R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006), 1903–1912.
5. 5 Leon, M.B., Baim, D.S., Popma, J.J., et al., for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998), 1665–1671.
6. 6 Schomig, A., Neumann, F.J., Kastrati, A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996), 1084–1089.
7. 7 Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 35 (2014), 2541–2619.
8. 8 Roffi, M., Patrono, C., Collet, J.P., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation. Eur Heart J 37 (2016), 267–315.
9. 9 January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
10. 10 Hansen, M.L., Sorensen, R., Clausen, M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170 (2010), 1433–1441.
11. 11 Holmes, D.R. Jr., Kereiakes, D.J., Kleiman, N.S., et al. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 54 (2009), 95–109.
12. 12 Zhao, H.J., Zheng, Z.T., Wang, Z.H., et al. “Triple therapy” rather than “triple threat”: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 139 (2011), 260–270.
13. 13 Ruiz-Nodar, J.M., Marin, F., Hurtado, J.A., et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation; implications for bleeding risk and prognosis. J Am Coll Cardiol 51 (2008), 818–825.
14. 14 Dewilde, W.J., Oirbans, T., Verheugt, F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
15. 15 Lamberts, M., Gislason, G.H., Olesen, J.B., et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 62 (2013), 981–989.
16. 16 Lamberts, M., Olesen, J.B., Ruwald, M.H., et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126 (2012), 1185–1193.
17. 17 Paikin, J.S., Wright, D.S., Crowther, M.A., Mehta, S.R., Eikelboom, J.W., Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 121 (2010), 2067–2070.
18. 18 Fiedler, K.A., Maeng, M., Mehilli, J., et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 65 (2015), 1619–1629.
19. 19 Faxon, D.P., Eikelboom, J.W., Berger, P.B., et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 106 (2011), 572–584.
20. 20 Sarafoff, N., Martischnig, A., Wealer, J., et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 61 (2013), 2060–2066.
21. 21 Cutlip, D.E., Windecker, S., Mehran, R., et al., for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
22. 22 Vranckx, P., Cutlip, D.E., Mehran, R., et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. Eurointervention 5 (2010), 871–874.
23. 23 Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
24. 24 Ndrepepa, G., Berger, P.B., Mehilli, J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008), 690–697.
25. 25 Koskinas, K.C., Räber, L., Zanchin, T., et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv, 8, 2015 e002053.
26. 26 Mehran, R., Baber, U., Steg, P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382 (2013), 1714–1722.
27. 27 Räber, L., Magro, M., Stefanini, G.G., et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125 (2012), 1110–1121.
28. 28 Jackson, L.R. II, Ju, C., Zettler, M., et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS Study. J Am Coll Cardiol Intv 8 (2015), 1880–1889.
29. 29 Valgimigli, M., Patialiakas, A., Thury, A., et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 65 (2015), 805–815.
30. 30 Feres, F., Costa, R.A., Abizaid, A., et al. Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310 (2013), 2510–2522.
31. 31 Bangalore, S., Kumar, S., Fusaro, M., et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125 (2012), 2873–2891.
32. 32 Verheugt, F.W., Do not use novel antiplatelet agents in patients on oral anticoagulants after stenting. J Am Coll Cardiol Intv 8 (2015), 1890–1892.